Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Recombinant human erythropoietin in the treatment of head and neck tumour anaemia
Autore:
Oettle, H; Riess, H; Raguse, JD; Bier, J; Gath, HJ;
Indirizzi:
Humboldt Univ, Fak Med, Charite Campus Virchow Klinikum, Med Klin & Poliklin MS Hamatol & Onokol, D-13353 Berlin, Germany Humboldt Univ Berlin Germany D-13353 l & Onokol, D-13353 Berlin, Germany Clin Oral & Maxillofacial Surg, D-13353 Berlin, Germany Clin Oral & Maxillofacial Surg Berlin Germany D-13353 53 Berlin, Germany
Titolo Testata:
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
fascicolo: 2, volume: 30, anno: 2001,
pagine: 148 - 155
SICI:
0901-5027(200104)30:2<148:RHEITT>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHEMOTHERAPY-INDUCED ANEMIA; CISPLATIN-ASSOCIATED ANEMIA; SQUAMOUS-CELL CARCINOMA; CANCER-RELATED ANEMIA; MULTIPLE-MYELOMA; DOUBLE-BLIND; SUBCUTANEOUS ERYTHROPOIETIN; MYELODYSPLASTIC SYNDROMES; INTENSIVE CHEMOTHERAPY; OXYGENATION PREDICTS;
Keywords:
squamous cell carcinoma; head-neck tumours; anaemia; radio-chemotherapy; recombinant human erythropoietin (r-HuEPO);
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
90
Recensione:
Indirizzi per estratti:
Indirizzo: Oettle, H Humboldt Univ, Fak Med, Charite Campus Virchow Klinikum, Med Klin & Poliklin MS Hamatol & Onokol, Augustenburger Pl 1, D-13353 Berlin, Germany Humboldt Univ Augustenburger Pl 1 Berlin Germany D-13353 ermany
Citazione:
H. Oettle et al., "Recombinant human erythropoietin in the treatment of head and neck tumour anaemia", INT J OR M, 30(2), 2001, pp. 148-155

Abstract

At the time of first diagnosis, patients with squamous cell carcinoma in the head and neck are often in the advanced stage of their disease, therefore surgery is not a viable option for treatment. These patients also presentfrequently a high grade of anaemia as a result of either the malignant process itself or of the following therapy. The incidence of anaemia and the need for transfusion depends on several factors, such as the type and intensity of radiotherapy and radiochemotherapy. Multimode therapeutic concepts such as radio-chemotherapy are being applied with increasing frequency, resulting in an ever increasing need for transfusion with great effects on the patient's quality of life. Even more important to tumour patients is the role of the haemaglobin (Hb) value as a prognostic factor for survival and/orlocal tumour control. A large number of studies show that recombinant human erythropoietin (r-HuEPO) is effective in the treatment of tumour-induced anaemia and prevention and correction of chemotherapy and radiotherapy-induced anaemia. The simultaneous application of r-HuEPO with chemotherapy can prevent patients with head and neck tumours from developing anaemia or can reduce the extent of the anaemia and the need for transfusion. Comparable effects were observed both in patients undergoing platinum-based and non-platinum-based chemotherapy. The direct correlation between anaemia, tumour hypoxia and poor response to radio and/or chemotherapy has been clinically proven. Recombinant human erythropoietin administration improves the therapeutic outcome and the patients' prognosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/09/20 alle ore 02:00:19